Refference
[1] Dell SD. Primary ciliary dyskinesia: Myths and realities.
Paediatr Child Health. 2008;13(8):668-70.
[2] Marthin JK, Petersen N, Skovgaard LT, Nielsen KG. Lung function
in patients with primary ciliary dyskinesia: a cross-sectional and
3-decade longitudinal study. Am J Respir Crit Care Med. 2010 Jun
1;181(11):1262-1268.
[3] Rubbo B, Best S, Hirst RA, Shoemark A, Goggin P, Carr SB,
Chetcuti P, Hogg C, Kenia P, Lucas JS et al. Clinical features and
management of children with primary ciliary dyskinesia in England. Arch
Dis Child. 2020 Aug;105(8):724-729.
[4] Prentice BJ, Wales S, Doumit M, Owens L, Widger J. Children with
bronchiectasis have poorer lung function than those with cystic fibrosis
and do not receive the same standard of care. Pediatr Pulmonol. 2019
Dec;54(12):1921-1926.
[5] Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins SA,
Hogg C, Kuehni CE, Lucas JS, Omran H, Quittner AL, et al. Study
protocol, rationale and recruitment in a European multi-centre
randomized controlled trial to determine the efficacy and safety of
azithromycin maintenance therapy for 6 months in primary ciliary
dyskinesia. BMC Pulm Med. 2016 Jul 22;16(1):104.
[6] Kobbernagel HE, Green K, Ring AM, Buchvald FF, Rosthøj S,
Gustafsson PM, Nielsen KG. One-year evolution and variability in
multiple-breath washout indices in children and young adults with
primary ciliary dyskinesia. Eur Clin Respir J. 2019 Mar 26;6(1):1591841.
[7] Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F,
Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, et al.
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The
OPTIMIZE Randomized Trial. Am J Respir Crit Care Med. 2018 Nov
1;198(9):1177-1187.
[8] Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne
D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention
of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a
randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:
660–67.
[9] Lee E, Sol IS, Kim JD, Yang HJ, Min TK, Jang GC, Hwang YH, Cho
HJ, Suh DI, Kim K, et al. Long-term macrolide treatment for non-cystic
fibrosis bronchiectasis in children: a meta-analysis. Sci Rep. 2021 Dec
20;11(1):24287.
[10] Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH,
Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin
maintenance treatment on infectious exacerbations among patients with
non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
JAMA 2013; 309: 1251–59.
[11] Yoshioka D, Sakamoto N, Ishimatsu Y, Kakugawa T, Ishii H, Mukae
H, Kadota J, Kohno S. Primary ciliary dyskinesia that responded to
long-term, low-dose clarithromycin. Intern Med. 2010;49(14):1437-40.
[12] Kido T, Yatera K, Yamasaki K, Nagata S, Choujin Y, Yamaga C,
Hara K, Ishimoto H, Hisaoka M, Mukae H. Two cases of primary ciliary
dyskinesia with different responses to macrolide treatment. Intern Med.
2012;51(9):1093-8.
[13] Marthin JK, Lucas JS, Boon M, Casaulta C, Crowley S, Destouches
DMS, Eber E, Escribano A, Haarman E, Hogg C, et al. International
BEAT-PCD consensus statement for infection prevention and control for
primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core
Network and patient representatives. ERJ Open Res. 2021 Aug
2;7(3):00301-2021.
[14] Kobbernagel HE, Buchvald FF, Haarman EG, Casaulta C, Collins
SA, Hogg C, Kuehni CE, Lucas JS, Moser CE, Quittner AL, et al. Efficacy
and safety of azithromycin maintenance therapy in primary ciliary
dyskinesia (BESTCILIA): a multicentre, double-blind, randomised,
placebo-controlled phase 3 trial. Lancet Respir Med. 2020
May;8(5):493-505.
[15] Guan Y, Yang H, Yao X, Xu H, Liu H, Tang X, Hao C, Zhang X,
Zhao S, Ge W, et al. Clinical and Genetic Spectrum of Children with
Primary Ciliary Dyskinesia in China. Chest. 2021 May;159(5):1768-1781.
[16] Paff T, Omran H, Nielsen KG, Haarman EG. Current and Future
Treatments in Primary Ciliary Dyskinesia. Int J Mol Sci. 2021 Sep
11;22(18):9834.
[17] Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ,
Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and
their relevance for clinical applications. Pharmacol Ther. 2014
Aug;143(2):225-45.
[18] Thomas D, McDonald VM, Simpson JL, Smith A, Gupta S, Majellano
E, et al. Patterns of azithromycin use in obstructive airway diseases: a
real-world observational study. Intern Med J. 2021 Feb 2.
[19] Pollock J, Chalmers JD. The immunomodulatory effects of
macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther. 2021
Dec;71: 102095.
[20] Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD,
Rosenfeld M, Olivier KN, Milla C, Daniel SJ, et al. Genetic Disorders of
Mucociliary Clearance Consortium. Diagnosis, monitoring, and treatment
of primary ciliary dyskinesia: PCD foundation consensus recommendations
based on state of the art review. Pediatr Pulmonol. 2016
Feb;51(2):115-32.
[21] Mirra V, Werner C, Santamaria F. Primary Ciliary Dyskinesia: An
Update on Clinical Aspects, Genetics, Diagnosis, and Future Treatment
Strategies. Front Pediatr. 2017 Jun 9;5:135.
[22] Goutaki M, Papon JF, Boon M, Casaulta C, Eber E, Escudier E,
Halbeisen FS, Harris A, Hogg C, Honore I, et al. Standardised clinical
data from patients with primary ciliary dyskinesia: FOLLOW-PCD. ERJ Open
Res. 2020 Feb 10;6(1):00237-2019.
[23] Halbeisen FS, Goutaki M, Spycher BD, Amirav I, Behan L, Boon M,
Hogg C, Casaulta C, Crowley S, Haarman EG, et al. Lung function in
patients with primary ciliary dyskinesia: an iPCD Cohort study. Eur
Respir J. 2018 Aug 23;52(2):1801040.
[24] Koh YY, Park Y, Jeong JH, Kim CK, Min YG, Chi JG. The effect of
regular salbutamol on lung function and bronchial responsiveness in
patients with primary ciliary dyskinesia. Chest. 2000 Feb;117(2):427-33.
[25] Shah A, Shoemark A, MacNeill SJ, Bhaludin B, Rogers A, Bilton
D, Hansell DM, Wilson R, Loebinger MR. A longitudinal study
characterising a large adult primary ciliary dyskinesia population. Eur
Respir J. 2016 Aug;48(2):441-50.
[26] Terpstra LC, Altenburg J, Mohamed Hoesein FA, Bronsveld I, Go
S, van Rijn PAC, De Jong PA, Heijerman HGM, Boersma WG. The effect of
maintenance azithromycin on radiological features in patients with
bronchiectasis-Analysis from the BAT randomized controlled trial. Respir
Med. 2021 Dec 28;192:106718.
[28] Goutaki M, Halbeisen FS, Spycher BD, Maurer E, Belle F, Amirav
I, Behan L, Boon M, Carr S, Casaulta C, et al. PCD Israeli Consortium;
Swiss PCD Group; French Reference Centre for Rare Lung Diseases. Growth
and nutritional status, and their association with lung function: a
study from the international Primary Ciliary Dyskinesia Cohort. Eur
Respir J. 2017 Dec 21;50(6):1701659.
[29] Maglione M, Bush A, Nielsen KG, Hogg C, Montella S, Marthin JK,
Di Giorgio A, Santamaria F. Multicenter analysis of body mass index,
lung function, and sputum microbiology in primary ciliary dyskinesia.
Pediatr Pulmonol. 2014 Dec;49(12):1243-50.
[30] Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA,
Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al.
Azithromycin for prevention of exacerbations of COPD. N Engl J Med.
2011;365:689–98.